Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172604 | 0.91 | GPR119 (0.48) | GPR119ERBB2CYP2C9CYP3A4 | |
| SCHEMBL10171891 | 0.91 | ERBB2 (0.46) | GPR119ERBB2KMT2ACYP2C9CYP3A4 | |
| SCHEMBL10171804 | 0.90 | GPR119 (0.47) | GPR119ERBB2KMT2ACYP2C9CYP3A4 | |
| SCHEMBL10172681 | 0.90 | GPR119 (0.45) | GPR119ERBB2KMT2ACYP2C9CYP3A4 | |
| SCHEMBL10172629 | 0.88 | GPR119 (0.44) | GPR119ERBB2ABL1KMT2ACYP2C9 | |
| SCHEMBL10172608 | 0.88 | GPR119 (0.44) | GPR119ERBB2KMT2ACYP2C9CYP3A4 | |
| SCHEMBL356735 | 0.86 | GPR119 (0.43) | GPR119ERBB2KMT2ACYP2C9CYP3A4 | |
| SCHEMBL10172682 | 0.85 | ERBB2 (0.47) | GPR119ERBB2KMT2ACYP2C9CYP3A4 | |
| SCHEMBL10171903 | 0.84 | GPR119 (0.48) | GPR119ERBB2KMT2ACYP2C9CYP3A4 | |
| SCHEMBL10172612 | 0.83 | GPR119 (0.48) | GPR119ERBB2KMT2ACYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | GPR119 1/4885ERBB2 451/4885KDM4E 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.